Sangamo Ch. 11 Auction Nets $238M In Offers

By Clara Geoghegan · August 20, 2026, 5:00 PM EDT

A Delaware bankruptcy judge Thursday agreed to approve a trio of sales that will bring in $52 million in cash for Sangamo Therapeutics, after attorneys representing the life sciences group told...

To view the full article, register now.

Bankruptcy Scorecard

Summary

Sangamo Therapeutics Inc. filed for bankruptcy protection in Delaware on Tuesday with offers to sell parts of its genetic therapy development programs to Eli Lilly and Co. and Astellas Pharma Inc.

Case Number

1:26-bk-10989

Judge

Craig Goldblatt

Venue

U.S. Bankruptcy Court for the District of Delaware

Capital Structure

Total Liabilities:

$100 million to $500 million

View Full Scorecard

Case Information

Case Title

Sangamo Therapeutics, Inc.

Case Number

1:26-bk-10989

Court

Delaware

Nature of Suit

Date Filed

June 23, 2026